Detection of Pneumocystis DNA in samples from patients suspected of bacterial pneumonia- a case-control study by Helweg-Larsen, Jannik et al.
BioMed  Central
Page 1 of 6
(page number not for citation purposes)
BMC Infectious Diseases
Open Access BMC Infectious Diseases  2002,  2 x Research article
Detection of Pneumocystis DNA in samples from patients suspected 
of bacterial pneumonia- a case-control study
Jannik Helweg-Larsen*1, Jørgen Skov Jensen2, Birthe Dohn2, 
Thomas L Benfield1 and Bettina Lundgren3
Address: 1Copenhagen HIV Programme, Department of Infectious Diseases, Copenhagen, Denmark, 2Neisseria Department, Statens Serum 
Institut, Copenhagen, Denmark and 3Department of Clinical Microbiology, Hvidovre Hospital, Copenhagen, Denmark
E-mail: Jannik Helweg-Larsen* - jhl@cphiv.dk; Jørgen Jensen - jsj@sss.dk; Birthe Dohn - jsj@ssi.dk; Thomas L Benfield - tlb@cphiv.dk; 
Bettina Lundgren - Bettina.Lundgren@hh.hosp.dk
*Corresponding author
Abstract
Background: Pneumocystis jiroveci (formerly known as P. carinii f.sp. hominis) is an opportunistic
fungus that causes Pneumocystis pneumonia (PCP) in immunocompromised individuals.
Pneumocystis jiroveci  can be detected by polymerase chain reaction (PCR). To investigate the clinical
importance of a positive Pneumocystis-PCR among HIV-uninfected patients suspected of bacterial
pneumonia, a retrospective matched case-control study was conducted.
Methods: Respiratory samples from 367 patients suspected of bacterial pneumonia were analysed
by PCR amplification of Pneumocystis jiroveci. To compare clinical factors associated with carriage of
P. jiroveci, a case-control study was done. For each PCR-positive case, four PCR-negative controls,
randomly chosen from the PCR-negative patients, were matched on sex and date of birth.
Results: Pneumocystis-DNA was detected in 16 (4.4%) of patients. The median age for PCR-
positive patients was higher than PCR-negative patients (74 vs. 62 years, p = 0.011). PCR-positive
cases had a higher rate of chronic or severe concomitant illness (15 (94%)) than controls (32 (50%))
(p = 0.004). Twelve (75%) of the 16 PCR positive patients had received corticosteroids, compared
to 8 (13%) of the 64 PCR-negative controls (p < 0.001).
Detection of Pneumocystis-DNA was associated with a worse prognosis: seven (44%) of patients
with positive PCR died within one month compared to nine (14%) of the controls (p = 0.01). None
of the nine PCR-positive patients who survived had developed PCP at one year of follow-up.
Conclusions: Our data suggest that carriage of Pneumocystis jiroveci is associated with old age,
concurrent disease and steroid treatment. PCR detection of P. jiroveci has low specificity for
diagnosing PCP among patients without established immunodeficiency. Whether overt infection is
involved in the poorer prognosis or merely reflects sub-clinical carriage is not clear. Further studies
of P. jiroveci in patients receiving systemic treatment with corticosteroids are warranted.
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Background
Pneumocystis pneumonia (PCP) is a common and serious
opportunistic infection in immunocompromised patients
that is caused by the fungal pathogen Pneumocystis jiroveci,
formerly known as P. carinii f.sp. hominis [1]. Because few
organisms are found in sputum and the sensitivity of mi-
croscopic examination of induced sputum is variable, the
diagnostic "gold standard" for PCP continues to be micro-
scopy of bronchoalveolar lavage (BAL) fluid. Although
BAL combined with conventional staining has high diag-
nostic sensitivity (>95%), this procedure is invasive. In or-
der to increase sensitivity in non-invasive specimens,
several experimental studies have evaluated PCR detec-
tion of P. jiroveci DNA as a potential diagnostic test.
We recently described a touch-down PCR method (TD-
PCR) with an internal control to detect PCR inhibition
[2,3]. On oral wash specimens obtained from HIV-1 in-
fected patients we found positive and negative predictive
values of 93 and 91% for the diagnosis of PCP [2]. Fur-
ther, this method had a 100% sensitivity and specificity
among 24 haematological cancer patients [3]. The aim of
the current study was to evaluate the clinical significance
and prevalence of a PCR positive signal in a broad spec-
trum of clinical samples from HIV-negative patients with
suspected bacterial pneumonia by means of an age and
sex matched nested case-control study.
Methods
Clinical specimens
A total of 367 respiratory specimens, including 100 BAL,
126 tracheal aspirates and 141 sputum samples, were ob-
tained from 367 patients suspected of pulmonary infec-
tion between November 1997 and August 1999. Of these,
261 specimens were randomly selected from specimens
submitted for detection of Mycoplasma pneumoniae or Le-
gionella pneumophila to Statens Serum Institut (SSI). The
remaining 106 respiratory samples represented all speci-
mens submitted for investigation of bacterial pneumonia
during a one-week period in August 1999, at the Depart-
ment of Clinical Microbiology, Herlev University Hospi-
tal.
DNA extraction and PCR
DNA was extracted as described [2]. To reduce the risk of
a false positive detection of P. jirovecii DNA, three distinct
genetic loci of Pneumocystis jiroveci were amplified by PCR
using primer sets that are specific for the human form of
Pneumocystis infection, Pneumocystis jiroveci.
Mitochondrial large subunit rRNA (mtLSU rRNA) was am-
plified by primers pAZ102 E and pAZ102H [4].
Mitochondrial small subunit rRNA (mtSSU rRNA) was am-
plified with primers pAZ112-10F and pAZ112-10R [5].
Major Surface Glycoprotein (MSG). Primers JKK14 and
JKK17 were used to amplify a highly conserved region of
the gene encoding the MSG [6].
The PCR methods amplifying the mtLSU and mtSSU loci
were chosen since these methods have been previously
validated and are in routine use at SSI [2]. The MSG meth-
od was chosen since this method was reported to have in-
creased sensitivity compared to amplification of mtLSU, a
finding which have been confirmed in our laboratory (da-
ta not shown) [6].
Internal process control for inhibition
To detect PCR inhibition, an internal process control was
constructed for each of the three primer sets [2]. When in-
hibition occurred, a 2-fold dilution of the DNA lysate was
retested.
Amplification protocol
PCR was carried out with Platinum Taq (Gibco), with re-
action mixtures as reported [2]. Precautions to avoid PCR
contamination included barrier methods, multiple nega-
tive controls and the use of dUTP. PCR was done blinded
to the identity of patients.
The cycling conditions for the mtLSU PCR included a
94°C preactivation of the enzyme for 2 minutes, 10 cycles
of touch-down PCR with a 1°C decrement of the anneal-
ing temperature per cycle from 72°C to 62°C, followed by
40 cycles with annealing at 62°C/30 seconds with dena-
turation at 94°C for 15 seconds and extension at 72°C for
15 seconds. Amplification of the mtSSU and MSG genes
were done with a touch down step from 65°C to 55°C fol-
lowed by 40 cycles at 55°C. PCR products were separated
on agarose gels with ethidium bromide staining.
Microscopy
Previously frozen PCR positive specimens were evaluated
by immunofluorescence staining detecting cyst according
to the manufactors protocol (Pasteur, France) [7].
Data and statistical analysis
Only samples positive by PCR amplification of all three P.
jiroveci genes were considered true PCR positive. Data on
age and sex were available from the laboratory. For each
of the 16 PCR-positive cases, we randomly selected four
controls matched by age and sex. Clinical data were col-
lected retrospectively by chart review. All 80 patients were
followed until October 2000. A clinical diagnosis of pneu-
monia was made if a newly developed infiltrate was found
on the chest X-ray at admission in association with an ap-
propriate clinical history and physical signs for which no
other cause was found. Isolation of pathogenic bacteria
from respiratory samples or blood culture from the day of
admission was considered as definitive microbial diagno-BMC Infectious Diseases 2002, 2 http://www.biomedcentral.com/1471-2334/2/28
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sis. One-month mortality was calculated from day of ad-
mission. None of the patients who died underwent
autopsy. Two-sided p values were calculated by Ficher's
exact test or Mann-Whitney tests with values of < 0.05
considered significant.
Results
A total of 16 patients (4 %) were considered true-PCR pos-
itive by amplification of the MSG, mtLSU and mtSSU
rRNA genes of Pneumocystis jiroveci (table 1). In addition,
5 samples were PCR positive with one or two primer sets
(three samples positive in one, two samples in two) but
tested negative with the third confirmatory PCR and were
considered as PCR negative. Among the 261 patients in-
vestigated for Legionella pneumophila or Mycoplasma pneu-
moniae pneumonia 11(4 %) were PCR positive compared
to 5 (5 %) of the 106 patients examined for bacterial in-
fection. The median age for PCR-positive patients was
higher than for the 346 PCR-negative patients (p = 0.025)
(table 1). None of the PCR-positive patients were known
to be HIV-1 positive at the time of specimen collection or
during the follow-up period. To our knowledge none of
the PCR-positive cases had been exposed to patients with
acute PCP, in particular none were hospitalized at infec-
tious disease departments, which in Denmark are treating
the majority of PCP cases. The cases did not receive anti-
pneumocystis treatment and were not hospitalised at the
same time or at the same hospital.
Two PCR-positive patients were investigated for PCP by
microscopy at time of diagnosis, based on fever, diffuse
interstitial infiltrates and high LDH occurring after chem-
otherapy for Hodgkins disease and pneumonia in the set-
ting of immunosuppressive treatment after renal
transplantation with delayed response to cefuroxime, re-
spectively. Both patients were negative for P. jiroveci. PCP
was not suspected or investigated in the remaining 14
PCR-positive patients or in any of the PCR-negative pa-
tients. P. jiroveci could not be detected by immunofluores-
cence microscopy in any of the PCR positive specimens.
The findings of the nested case-control study, which com-
pared the 16 patients with a positive P. jiroveci PCR to 64
age and sex matched PCR-negative controls, are summa-
rized in table 2. PCR-positive cases had a higher rate of
chronic or severe concomitant illness (15 (94%)) com-
pared to controls (32 (50%)) (p = 0.004) (Table 2). By
comparison of the one-month mortality, seven (44%) cas-
es died compared to nine (14%) of the controls (p =
0.014). In all patients death was due to pneumonia and
respiratory failure. Among the seven PCR positive patients
who died, five had chronic pulmonary disease (COPD),
one patient Hodgkin's disease and one patient no prior
medical history. H. influenzae pneumonia was diagnosed
in three patients and S. pneumoniae pneumonia in one. At
one year of follow-up, none of the 9 surviving patients
had developed Pneumocystis jiroveci pneumonia.
A higher proportion of PCR-positive patients compared to
controls had received treatment with steroids alone (10/
16 versus 7/64, p < 0.001). In addition, two of the PCR-
positive patients were currently immunosuppressed by
high-dose chemotherapy or azathioprine, in contrast to
controls, of whom none received other immunosuppres-
sive agents at diagnosis. Among patients treated with cor-
ticosteroids, the duration of corticosteroid treatment was
longer (p < 0.001, Mann-Whitney) and the prednisone
dosage was higher (median prednisone dosage 37.5 vs.
7.5 mg, p = 0.026) in cases compared to controls. Howev-
er, three of the PCR-positive cases had only received two
weeks of corticosteroid treatment. Of the four PCR-posi-
tive cases without identified cause of immunosuppres-
sion, two patients had verified bacterial pneumonia and
two patients had pneumonia of unknown cause. All four
patients were old (age 59 to 80 years) with chronic ob-
structive pulmonary disease (COPD) and/or ischaemic
heart disease (IHD).
Discussion
In this study, P. jiroveci was detected by PCR in 16 (4 %)
of 367 HIV-negative patients suspected of bacterial pneu-
monia. High age, systemic corticosteroid treatment and a
high rate of concurrent illnesses were associated with the
finding of a positive P. jiroveci PCR. Although the detec-
tion of Pneumocystis DNA was associated with a poor
prognosis, more than half of the patients recovered with-
out treatment of PCP indicating that these patients were
colonised or had sub-clinical infection.
In patients without AIDS, treatment with corticosteroids,
chemotherapy or other immunosuppressive agents are
well established risk factors of clinical PCP [8–10]. PCP is
mostly seen following high dose corticosteroid treatment,
but no threshold level for immunosuppression exists and
even low doses of corticosteroid therapy may predispose
to PCP [10]. In clinical practice, however, PCP is rarely
Table 1: Characteristics of respiratory specimens.
PCR-negative PCR-positive
Respiratory specimens
BAL 96 4 (4%)
Tracheal aspirates 116 7 (6%)
Sputum 134 5 (4%)
Median Age (range), years 62 (1–91) 74* (47–88)
Male / female 195 / 151 6 / 10
* p = 0.011, Mann-Whitney.BMC Infectious Diseases 2002, 2 http://www.biomedcentral.com/1471-2334/2/28
Page 4 of 6
(page number not for citation purposes)
considered in patients presenting with pneumonia, except
patients with known predisposing factors such as HIVHIV,
chemotherapy treated malignancy or transplant related
immunosuppression. In the current study, PCP was sus-
pected in only two patients with lymphoma and trans-
plantation. Interestingly, three PCR-positive patients had
only received corticosteroid treatment for two weeks, sug-
gesting that even short-term immunosuppression may
predispose to colonisation.
Previously, several studies have evaluated the use of PCR
for diagnosis of PCP [4,7,11]. Most studies have found
that PCR is more sensitive than conventional staining
methods with the ability to detect infection in oral wash,
sputum and tracheal aspirates, in which conventional
staining has inadequate sensitivity. These samples are
considerably easier to obtain than BAL. The use of nested
PCR have been shown to increase sensitivity in compari-
son with single-round PCR, however the additional ma-
nipulations increase the risk of false positive results
[11,12]. Consequently, an optimised single round PCR
protocol (TD-PCR) has been chosen for routine use at
Statens Serum Institut [2].
The exact mode of acquisition and transmission of P. ji-
roveci has been debated but is still not completely under-
stood. For many years PCP was believed to be caused by
reactivation of latent infection based on a high prevalence
of persistent antibodies to P. jiroveci from an early age
[13,14]. This view was changed when it was observed that
animal hosts [15,16] and immunocompetent individuals
[17] do not seem to carry Pneumocystis after primary infec-
tion. Hence, infection is now primarily believed to be
caused by new infection, rather than reactivation of latent
organisms. But if infection is cleared, what constitutes the
source of new infections? Although the natural reservoir
for P. jiroveci remains undefined, recent experimental ani-
mal studies and studies in humans have suggested that
Table 2: Clinical characteristic of 16 P. jiroveci PCR-positive patients and 64 age and sex matched PCR-negative controls.
PCR-positive patients PCR-negative patients p-value
N1 6 6 4
Age, years 73 (53–78) 71 (51–78)
Male / female 6 / 10 24 / 40
Dead within one-month 7 (44%) 9 (14%) p = 0.014
Diagnosis (%)
Bacterial pneumonia (verified) 3 (19%) 13 (20%)
Pneumonia, pathogen not identified 6 (39%) 31 (48%)
Acute bronchitis 5 (31%) 12 (19%)
Lung malignancy 0 2 (3%)
Cardiac disease 1 (6%) 4 (6%)
Other 1 (6%) 3 (5%)
Concurrent diseases (%)
Unknown/None 1 (6%) 32 (50%)
COPD 10 (63%) 13 (20%)
Malignancy 1 (6%) 4 (6%)
Lymphoma and bone marrow-transplant 1 (6%) 1 (2%)
NYHA III/IV 1 (6%) 13 (20%)
NYHA III/IV and COPD 1 (6%) 1 (2%)
Chronic renal failure 0 1 (2%)
Renal transplantation and malignancy 1 (6%) 0
Total number with concurrent diseases 15 (94%) 32 (50%) p = 0.004
Immunosuppressive therapy (%)
None 4 (25%) 56 (87%)
Steroids alone 10 (63%) 7 (11%) p < 0.001
Chemotherapy alone 0 1 (2%)
Chemotherapy and steroids 1 (6%) 0
Azathioprine and steroids 1 (6%) 0
Total number receiving steroids 12 (75%) 8 (13%)
Corticosteroid dosea 37,5 (8,8–58,8) 7.5 (5–27,5) p = 0.026
Duration of corticosteroid therapy, weeks (range) 66 (1–102) 8 (1–42) p < 0.001
All values are Median (25–75 percentiles). a Corticosteroid dose in daily equivalents of prednisone in milligrams at time of diagnosis. COPD: 
Chronic obstructive pulmonary disease. NYHA: New York Heart Association.BMC Infectious Diseases 2002, 2 http://www.biomedcentral.com/1471-2334/2/28
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asymptomatic immunocompetent carriers may be one
source of infection. Immunocompetent mice can be tran-
siently colonised with P. carinii and are able to transmit
the infection to mice with severe combined immunodefi-
ciency [18]. In humans subclinical colonisation have been
described in both immunosuppresed and immunocom-
petent individuals by PCR. However, the extent of coloni-
sation has been debated with different rates of P. jiroveci
carriage reported. Nevez et al. reported that 20 % of 169
HIV-negative patients with moderate or severe immuno-
suppression were positive by nested PCR; none of the pa-
tients developed PCP [19]. In agreement with this study
studies by Olsson et al and Takahashi et al reported a PCR
positive rates of 28% and 20%, respectively among HIV-
negative immunosuppressed patients without definite or
probable PCP [20,21]. Sing et al. found by nested PCR
that 17–20% of immunocompetent patients with primary
pulmonary disorders were nested PCR positive without
developing PCP [11,22]. These observations suggest that
colonization with P. jiroveci may be more common than
previously thought, even in immunocompetent individu-
als. However, in contrast to Sing et al, we observed a much
lower rate of PCR positivity (4%) among our patients with
community-acquired pneumonia.
Whether the relatively low rate of P. jiroveci detection is a
result of real population based differences in P. jiroveci
carrier rates or stems from differences in PCR methods is
unknown. PCR is extremely sensitive and will detect both
living and dead organisms. A positive PCR in an asympto-
matic patient could reflect PCR contamination, coloniza-
tion or transient carriage of a very low number of P. jiroveci
organisms. In our study, the risk of false positive reactions
was reduced by only considering samples true PCR posi-
tive if three different P. jiroveci gene targets could be am-
plified, whereas the other studies [11,19,22]. only
amplified a single gene with nested PCR, which may in-
crease the risk of false positive signals. In 5 patients we de-
tected P. jiroveci DNA with one or two of the three PCR
primer amplifications but failed to generate a PCR signal
in the third confirmatory setup. These samples possibly
represent cases in which the P. jiroveci DNA was at the
threshold of detection. Interestingly, the frequency of pos-
itive specimens were comparable in BAL, tracheal aspi-
rates and sputum (4–6%) and were equivalent in patients
suspected of bacterial and atypical bacterial pneumonia
(3–4%), suggesting that the rate of positive specimens was
not related to respiratory sample type. Further, nosocomi-
al transmission was unlikely, since the patients were not
admitted to the same ward. The low rate of PCR positivity
we observe is comparable to reports by Visconti et al [23],
where only 2.5% of 78 immunocompetent patients were
positive by nested PCR; Oz et al [24], in which no P. carinii
DNA by single PCR were detected in any of 258 upper res-
piratory tract specimens from 86 immunocompetent indi-
viduals in the absence of microscopy verified PCP, and a
Danish study[25] where 4.7% of 1762 consecutive lung
biopsies at autopsy were microscopically positive for P.
carinii [25].
Because of the retrospective design and limited sample
size, our study has limitations. The clinical significance of
a positive P. jiroveci PCR is unclear. In terms of demo-
graphics and comorbidities, a wide spectrum of patients
was included with an overall low pre-test probability of
PCP, which were only clinically suspected in a few pa-
tients. A higher mortality (54%) was observed in PCR-
positive cases compared to controls (18%), a rate that is
similar to the 18% mortality rate reported for elderly pa-
tients with community-acquired pneumonia [26]. How-
ever, since autopsies were not done, the causes of deaths
are unknown. Whether detection of P. jiroveci is an inde-
pendent predictor of death or merely a marker of severe
illness is therefore not known. We were unable to detect
P. jiroveci by microscopy in any of the 16 PCR-positive
samples, indicating that the number of organisms was be-
low the detection limit of conventional staining. Howev-
er, 10 of the samples were sputum or tracheal aspirates, in
which microscopy has limited diagnostic sensitivity. Fur-
ther, 9 of the PCR positive patients recovered without spe-
cific anti-pneumocystis treatment and another pulmonary
infection were found in 4 patients. Nevertheless, these
finding do not rule out that P. jiroveci may have contribut-
ed to the severity of clinical disease since concomitant pul-
monary infections may be detected in 35–58% of AIDS-
associated PCP [8,10].
Conclusions
Our results show, that P. jiroveci may more easily colonise
individuals with severe or concomitant disease, in partic-
ular in connection with steroid treatment. These individ-
uals may represent a possible reservoir for the circulation
of Pneumocystis organisms in the community. Because P.
jiroveci DNA was also detected in immunocompetent indi-
viduals recovering without specific anti pneumocystis
therapy, our results support that subclinical infection or
colonisation may happen in adult immunocompetent in-
dividuals, although rarely. Our findings affirm that the in-
terpretation of a positive PCR must be done with great
caution, in particular in patients without known risk fac-
tors for PCP. In such patients, confirmation of PCP should
preferably be sought by conventional staining methods.
Possibly, a improved method of PCR diagnosis may be
quantitative PCR, since recent research suggest that appli-
cation of a cut-off value to quantitative PCR could have a
role in distinguishing between colonisation and clinical
disease [27]. Additional studies of colonisation and the
possible pathogenic role of P. jiroveci in patients without
HIV, in particular COPD patients are warranted.BMC Infectious Diseases 2002, 2 http://www.biomedcentral.com/1471-2334/2/28
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